Nektar Therapeutics Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 76.01K shares, a 47.21% decline from fiscal 2024.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 144.00K shares.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 15.00K shares, a 99.40% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 76.01K shares 10-K · filed 2026-03-13 | |
| 2024-12-31 | 144.00K shares 10-K · filed 2025-03-14 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2024-03-05 | |
| 2022-12-31 | 15.00K shares 10-K · filed 2023-02-28 | |
| 2021-12-31 | 2.48M shares 10-K · filed 2022-03-01 | |
| 2020-12-31 | 1.67M shares 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |